Literature DB >> 23836420

O-GlcNAc in cancer biology.

Zhiyuan Ma1, Keith Vosseller.   

Abstract

O-linked β-N-actylglucosamine (O-GlcNAc) is a carbohydrate post-translational modification on hydroxyl groups of serine and/or threonine residues of cytosolic and nuclear proteins. Analogous to phosphorylation, O-GlcNAcylation plays crucial regulatory roles in a variety of cellular processes. O-GlcNAc was termed a nutritional sensor, as global levels of the modification are elevated in response to increased glucose and glutamine flux into the hexosamine biosynthetic pathway. A unique feature of cancer cell energy metabolism is a shift from oxidative phosphorylation to the less efficient glycolytic pathway (Warburg effect), necessitating greatly increased glucose uptake. Additionally, to help meet increased biosynthetic demands, cancer cells also up-regulate glutamine uptake. This led us to hypothesize that the universal feature of increased glucose and glutamine uptake by cancer cells might be linked to increased O-GlcNAc levels. Indeed, recent work in many different cancer types now indicates that hyper-O-GlcNAcylation is a general feature of cancer and contributes to transformed phenotypes. In this review, we describe known/potential links between hyper-O-GlcNAcylation and specific hallmarks of cancer, including cancer cell proliferation, survival, cell stresses, invasion and metastasis, aneuploidy, and energy metabolism. We also discuss inhibition of hyper-O-GlcNAcylation as a potential novel therapeutic target for cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23836420     DOI: 10.1007/s00726-013-1543-8

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  78 in total

Review 1.  Nutrient regulation of signaling and transcription.

Authors:  Gerald W Hart
Journal:  J Biol Chem       Date:  2019-01-09       Impact factor: 5.157

2.  Is pulmonary hypertension a metabolic disease?

Authors:  Jarrod Barnes; Raed A Dweik
Journal:  Am J Respir Crit Care Med       Date:  2014-11-01       Impact factor: 21.405

3.  The New Chemical Reporter 6-Alkynyl-6-deoxy-GlcNAc Reveals O-GlcNAc Modification of the Apoptotic Caspases That Can Block the Cleavage/Activation of Caspase-8.

Authors:  Kelly N Chuh; Anna R Batt; Balyn W Zaro; Narek Darabedian; Nicholas P Marotta; Caroline K Brennan; Arya Amirhekmat; Matthew R Pratt
Journal:  J Am Chem Soc       Date:  2017-05-31       Impact factor: 15.419

4.  Changes in O-Linked N-Acetylglucosamine (O-GlcNAc) Homeostasis Activate the p53 Pathway in Ovarian Cancer Cells.

Authors:  Rafaela Muniz de Queiroz; Rashna Madan; Jeremy Chien; Wagner Barbosa Dias; Chad Slawson
Journal:  J Biol Chem       Date:  2016-07-11       Impact factor: 5.157

Review 5.  O-GlcNAc signaling in cancer metabolism and epigenetics.

Authors:  Jay Prakash Singh; Kaisi Zhang; Jing Wu; Xiaoyong Yang
Journal:  Cancer Lett       Date:  2014-04-24       Impact factor: 8.679

Review 6.  The regulatory roles of O-GlcNAcylation in mitochondrial homeostasis and metabolic syndrome.

Authors:  Lin Zhao; Zhihui Feng; Xiaoyong Yang; Jiankang Liu
Journal:  Free Radic Res       Date:  2016-10-19

7.  The Sulfur-Linked Analogue of O-GlcNAc (S-GlcNAc) Is an Enzymatically Stable and Reasonable Structural Surrogate for O-GlcNAc at the Peptide and Protein Levels.

Authors:  Cesar A De Leon; Paul M Levine; Timothy W Craven; Matthew R Pratt
Journal:  Biochemistry       Date:  2017-06-30       Impact factor: 3.162

Review 8.  Regulation of cancer metabolism by O-GlcNAcylation.

Authors:  Zhonghua Li; Wen Yi
Journal:  Glycoconj J       Date:  2013-12-10       Impact factor: 2.916

9.  Metabolic Labeling for the Visualization and Identification of Potentially O-GlcNAc-Modified Proteins.

Authors:  Nichole J Pedowitz; Balyn W Zaro; Matthew R Pratt
Journal:  Curr Protoc Chem Biol       Date:  2020-06

10.  Gluconeogenic enzyme PCK1 deficiency promotes CHK2 O-GlcNAcylation and hepatocellular carcinoma growth upon glucose deprivation.

Authors:  Jin Xiang; Chang Chen; Rui Liu; Dongmei Gou; Lei Chang; Haijun Deng; Qingzhu Gao; Wanjun Zhang; Lin Tuo; Xuanming Pan; Li Liang; Jie Xia; Luyi Huang; Ke Yao; Bohong Wang; Zeping Hu; Ailong Huang; Kai Wang; Ni Tang
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.